Participants 70 84 3
uveal melanoma
Participants 524 686 7
conducted from August 2010 through December 2013 among 120 patients with metastatic uveal melanoma at 15 academic oncology centers in the United States and Canada
Participants 702 1000 4
One hundred one patients were randomized in a 1:1 ratio to receive selumetinib, 75 mg orally twice daily on a continual basis (nâ€‰=â€‰50), or chemotherapy (temozolomide, 150 mg/m2 orally daily for 5 of every 28 days, or dacarbazine, 1000 mg/m2 intravenously every 21 days [investigator choice]; nâ
Participants 1123 1251 4
alysis, 19 patients were registered and 18 treated with selumetinib without randomization to complete the planned 120-patient en
Participants 2587 2624 3
rating study of patients with advance
